(thirdQuint)Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients.

 Crizotinib is indicated in the U.

S.

 for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

 Commercially available dosage forms are 250 mg and 200 mg capsules.

 This expanded access protocol (EAP) is designed to provide access to an alternative oral formulation of crizotinib for those patients who are unable to swallow capsules.

.

 Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients@highlight

This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal translocation or activating mutation involving the ALK or ROS1 gene or an activating genetic alteration involving the cMET gene who cannot swallow the crizotinib capsule but may be able to derive benefit from treatment with an alternative oral formulation of crizotinib.

